Abstract
Background: Severe Asthma Network in Italy (SANI) is a registry of patients recruited by accredited centers on severe asthma. Objective: To analyze epidemiological, clinical, inflammatory, functional, and treatment characteristics of severe asthmatics from the SANI registry. Methods: All consecutive patients with severe asthma were included into the registry, without exclusion criteria to have real-life data on demographics, asthma control, treatments (including biologics), inflammatory biomarkers, and comorbidities. Results: A total of 437 patients (mean age: 54.1 years, 57.2% females, 70.7% atopics, 94.5% in Global Initiative for Asthma severity step V) were enrolled into the study. The mean annual exacerbation rate was 3.75. The mean blood eosinophil level was 536.7 cells/mcL, and the average serum total IgE was 470.3 kU/L. Approximately 64% of patients were on regular oral corticosteroid treatment, 57% with omalizumab and 11.2% with mepolizumab. Most common comorbidities were rhinitis, nasal polyposis, and bronchiectasis. Patients with nasal polyposis had higher age of disease onset, higher blood eosinophil count, and lower frequency of atopy and atopic eczema. Bronchiectasis was associated with more frequent severe exacerbations, higher blood eosinophils, and total IgE. Stratifying patients, those with late-onset asthma were less frequently atopic (with less frequent allergic rhinitis and food allergy), and more frequently with nasal polyposis and higher serum total IgE levels. Conclusions: This study revealed a high frequency of relevant comorbidities and that a substantial proportion of patients have late-onset asthma; all these features define specific different disease phenotypes. Severe asthma complexity and comorbidities require multidisciplinary approaches, led by specifically trained pulmonologists and allergists.
| Original language | English |
|---|---|
| Pages (from-to) | 1462-1468 |
| Journal | Journal of Allergy and Clinical Immunology: In Practice |
| Volume | 7 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - 2019 |
Fingerprint
Keywords
- Bronchiectasis
- Comorbidities
- Late-onset asthma
- Nasal polyps
- Registry
- SANI
- Severe asthma
ASJC Scopus subject areas
- Immunology and Allergy
Cite this
The Severe Asthma Network in Italy : Findings and Perspectives. / SANI Network ; Heffler, Enrico; Blasi, Francesco; Latorre, Manuela; Menzella, Francesco; Paggiaro, Pierluigi; Pelaia, Girolamo; Senna, Gianenrico; Canonica, Giorgio Walter.
In: Journal of Allergy and Clinical Immunology: In Practice, Vol. 7, No. 5, 2019, p. 1462-1468.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The Severe Asthma Network in Italy
T2 - Findings and Perspectives
AU - SANI Network
AU - Heffler, Enrico
AU - Blasi, Francesco
AU - Latorre, Manuela
AU - Menzella, Francesco
AU - Paggiaro, Pierluigi
AU - Pelaia, Girolamo
AU - Senna, Gianenrico
AU - Canonica, Giorgio Walter
AU - Barbuto, Sarah
AU - Bradicich, Matteo
AU - Camiciottoli, Gianna
AU - Caminati, Marco
AU - Colombo, Giselda
AU - Costantino, Maria Teresa
AU - Crimi, Nunzio
AU - Crivellaro, Mariangiola
AU - D'Adda, Alice
AU - D'Amato, Mariella
AU - Favero, Elisabetta
AU - Foschino, Maria Pia
AU - Galeone, Carla
AU - Guarnieri, Gabriella
AU - Lombardi, Carlo
AU - Parente, Roberta
AU - Passalacqua, Giovanni
AU - Patella, Vincenzo
AU - Puggioni, Francesca
AU - Ridolo, Erminia
AU - Rolla, Giovanni
AU - Savi, Eleonora
AU - Scichilone, Nicola
AU - Solidoro, Paolo
AU - Spadaro, Giuseppe
PY - 2019
Y1 - 2019
N2 - Background: Severe Asthma Network in Italy (SANI) is a registry of patients recruited by accredited centers on severe asthma. Objective: To analyze epidemiological, clinical, inflammatory, functional, and treatment characteristics of severe asthmatics from the SANI registry. Methods: All consecutive patients with severe asthma were included into the registry, without exclusion criteria to have real-life data on demographics, asthma control, treatments (including biologics), inflammatory biomarkers, and comorbidities. Results: A total of 437 patients (mean age: 54.1 years, 57.2% females, 70.7% atopics, 94.5% in Global Initiative for Asthma severity step V) were enrolled into the study. The mean annual exacerbation rate was 3.75. The mean blood eosinophil level was 536.7 cells/mcL, and the average serum total IgE was 470.3 kU/L. Approximately 64% of patients were on regular oral corticosteroid treatment, 57% with omalizumab and 11.2% with mepolizumab. Most common comorbidities were rhinitis, nasal polyposis, and bronchiectasis. Patients with nasal polyposis had higher age of disease onset, higher blood eosinophil count, and lower frequency of atopy and atopic eczema. Bronchiectasis was associated with more frequent severe exacerbations, higher blood eosinophils, and total IgE. Stratifying patients, those with late-onset asthma were less frequently atopic (with less frequent allergic rhinitis and food allergy), and more frequently with nasal polyposis and higher serum total IgE levels. Conclusions: This study revealed a high frequency of relevant comorbidities and that a substantial proportion of patients have late-onset asthma; all these features define specific different disease phenotypes. Severe asthma complexity and comorbidities require multidisciplinary approaches, led by specifically trained pulmonologists and allergists.
AB - Background: Severe Asthma Network in Italy (SANI) is a registry of patients recruited by accredited centers on severe asthma. Objective: To analyze epidemiological, clinical, inflammatory, functional, and treatment characteristics of severe asthmatics from the SANI registry. Methods: All consecutive patients with severe asthma were included into the registry, without exclusion criteria to have real-life data on demographics, asthma control, treatments (including biologics), inflammatory biomarkers, and comorbidities. Results: A total of 437 patients (mean age: 54.1 years, 57.2% females, 70.7% atopics, 94.5% in Global Initiative for Asthma severity step V) were enrolled into the study. The mean annual exacerbation rate was 3.75. The mean blood eosinophil level was 536.7 cells/mcL, and the average serum total IgE was 470.3 kU/L. Approximately 64% of patients were on regular oral corticosteroid treatment, 57% with omalizumab and 11.2% with mepolizumab. Most common comorbidities were rhinitis, nasal polyposis, and bronchiectasis. Patients with nasal polyposis had higher age of disease onset, higher blood eosinophil count, and lower frequency of atopy and atopic eczema. Bronchiectasis was associated with more frequent severe exacerbations, higher blood eosinophils, and total IgE. Stratifying patients, those with late-onset asthma were less frequently atopic (with less frequent allergic rhinitis and food allergy), and more frequently with nasal polyposis and higher serum total IgE levels. Conclusions: This study revealed a high frequency of relevant comorbidities and that a substantial proportion of patients have late-onset asthma; all these features define specific different disease phenotypes. Severe asthma complexity and comorbidities require multidisciplinary approaches, led by specifically trained pulmonologists and allergists.
KW - Bronchiectasis
KW - Comorbidities
KW - Late-onset asthma
KW - Nasal polyps
KW - Registry
KW - SANI
KW - Severe asthma
UR - http://www.scopus.com/inward/record.url?scp=85057268805&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85057268805&partnerID=8YFLogxK
U2 - 10.1016/j.jaip.2018.10.016
DO - 10.1016/j.jaip.2018.10.016
M3 - Article
AN - SCOPUS:85057268805
VL - 7
SP - 1462
EP - 1468
JO - Journal of Allergy and Clinical Immunology: In Practice
JF - Journal of Allergy and Clinical Immunology: In Practice
SN - 2213-2198
IS - 5
ER -